These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23722431)

  • 1. Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses.
    Solomon K; Martin AJ; O'Donoghue C; Chen X; Fenelon L; Fanning S; Kelly CP; Kyne L
    J Med Microbiol; 2013 Sep; 62(Pt 9):1453-1460. PubMed ID: 23722431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune response as predictor of recurrence in Clostridium difficile infection.
    Bauer MP; Nibbering PH; Poxton IR; Kuijper EJ; van Dissel JT
    Clin Microbiol Infect; 2014 Dec; 20(12):1323-8. PubMed ID: 25041274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
    Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
    PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
    Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
    mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.
    von Eichel-Streiber A; Paik W; Knight K; Gisch K; Nadjafi K; Decker C; Bosnjak O; Cheknis A; Johnson S; von Eichel-Streiber C
    Anaerobe; 2016 Oct; 41():91-103. PubMed ID: 27427464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
    Kyne L; Warny M; Qamar A; Kelly CP
    N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
    Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
    Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High morbidity and mortality of Clostridium difficile infection and its associations with ribotype 002 in Hong Kong.
    Wong SH; Ip M; Hawkey PM; Lo N; Hardy K; Manzoor S; Hui WW; Choi KW; Wong RY; Yung IM; Cheung CS; Lam KL; Kwong T; Wu WK; Ng SC; Wu JC; Sung JJ; Lee N
    J Infect; 2016 Aug; 73(2):115-22. PubMed ID: 27246801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value.
    von Bechtolsheim F; Varga A; Szereday L; Polgar B; Balassa T; Kocsis B; Peterfi Z; Miko E
    J Microbiol Methods; 2019 Dec; 167():105777. PubMed ID: 31733265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis.
    Negm OH; Hamed MR; Dilnot EM; Shone CC; Marszalowska I; Lynch M; Loscher CE; Edwards LJ; Tighe PJ; Wilcox MH; Monaghan TM
    Clin Vaccine Immunol; 2015 Sep; 22(9):1033-9. PubMed ID: 26178385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality.
    Rao K; Micic D; Natarajan M; Winters S; Kiel MJ; Walk ST; Santhosh K; Mogle JA; Galecki AT; LeBar W; Higgins PD; Young VB; Aronoff DM
    Clin Infect Dis; 2015 Jul; 61(2):233-41. PubMed ID: 25828993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.
    Monaghan TM; Robins A; Knox A; Sewell HF; Mahida YR
    PLoS One; 2013; 8(9):e74452. PubMed ID: 24058568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.
    Hughes M; Qazi T; Berg A; Weinberg J; Chen X; Kelly CP; Farraye FA
    Inflamm Bowel Dis; 2016 Apr; 22(4):853-61. PubMed ID: 26954708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
    Steele J; Mukherjee J; Parry N; Tzipori S
    J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.
    Yang Z; Shi L; Yu H; Zhang Y; Chen K; Saint Fleur A; Bai G; Feng H
    Pathog Dis; 2016 Oct; 74(7):. PubMed ID: 27502696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
    Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
    Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
    Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
    BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.